# Syncom Formulations (India) (NSE: SYNCOMF) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SYNCOMF · Pivot · prices to 22 Oct 2026

Syncom Formulations (India) (NSE: SYNCOMF) closed at ₹22.83 on 22 Oct 2026, up 3.21% on the day. With a market capitalisation of ₹2,146 Cr, it ranks 1116th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 28.2× trailing earnings, against a return on equity of 18.4% in FY26. Over the past year the share price has risen 38.8%. Its 52-week range is ₹10.21 (30 Mar 2026) to ₹27.49 (30 Sep 2026); the last close is 17.0% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹135 Cr (−9.0% year on year) and net profit ₹25 Cr (+42.3%), on a consolidated basis. Promoters held 50.57% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹22.83 |
| Market cap | ₹2,146 Cr |
| P/E (trailing) | 28.2 |
| ROE | 18.4% (FY26) |
| ROCE | 23.8% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹27.49 (30 Sep 2026) |
| 52-week low | ₹10.21 (30 Mar 2026) |
| 1-year return | +38.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹135 Cr | −9.0% | ₹25 Cr | +42.3% | ₹0.27 |
| Q3 FY26 | ₹115 Cr | −9.7% | ₹19 Cr | +45.5% | ₹0.23 |
| Q2 FY26 | ₹122 Cr | +19.0% | ₹17 Cr | +49.4% | ₹0.18 |
| Q1 FY26 | ₹117 Cr | +34.0% | ₹16 Cr | +106.4% | ₹0.21 |
| Q4 FY25 | ₹149 Cr | +99.7% | ₹18 Cr | +139.1% | ₹0.16 |
| Q3 FY25 | ₹128 Cr | +95.8% | ₹13 Cr | +85.7% | ₹0.14 |
| Q2 FY25 | ₹102 Cr | +60.3% | ₹11 Cr | +70.7% | ₹0.16 |
| Q1 FY25 | ₹87 Cr | +45.8% | ₹8 Cr | +73.4% | ₹0.11 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹465 Cr | ₹49 Cr |
| FY24 | ₹263 Cr | ₹25 Cr |
| FY23 | ₹224 Cr | ₹20 Cr |
| FY22 | ₹220 Cr | ₹20 Cr |
| FY17 | ₹185 Cr | ₹11 Cr |
| FY16 | ₹184 Cr | ₹10 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 50.57%
- Foreign institutions: 0.35%
- Domestic institutions: 0.00%
- Non-institutions: 49.08%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Dishman Carbogen Amcis](https://app.pivotnow.in/stock/DCAL) | ₹141.95 | ₹2,226 Cr | 22.8 | — |
| [Vimta Labs](https://app.pivotnow.in/stock/VIMTALABS) | ₹495.55 | ₹2,214 Cr | 28.5 | — |
| [Medi Assist Healthcare Services](https://app.pivotnow.in/stock/MEDIASSIST) | ₹291.75 | ₹2,179 Cr | 24.1 | — |
| [Indoco Remedies](https://app.pivotnow.in/stock/INDOCO) | ₹230.55 | ₹2,128 Cr | — | — |
| [Panacea Biotec](https://app.pivotnow.in/stock/PANACEABIO) | ₹335.85 | ₹2,057 Cr | — | — |
| [Sakar Healthcare](https://app.pivotnow.in/stock/SAKAR) | ₹923.90 | ₹2,056 Cr | 67.6 | — |

## Questions and answers

### What is the share price of Syncom Formulations (India) today?

Syncom Formulations (India) (NSE: SYNCOMF) last closed at ₹22.83 on 22 Oct 2026. Its 52-week high is ₹27.49 and its 52-week low is ₹10.21.

### What is the market cap of Syncom Formulations (India)?

Syncom Formulations (India)'s market capitalisation is ₹2,146 Cr (₹2,146 Cr) at the 22 Oct 2026 close, ranking 1116th among the NSE companies Pivot tracks.

### What is the P/E ratio of Syncom Formulations (India)?

Syncom Formulations (India) trades at a trailing P/E of 28.2. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 28.5.

### What is the ROE and ROCE of Syncom Formulations (India)?

Return on equity was 18.4% in FY26 and return on capital employed was 23.8% in FY26 (consolidated figures).

### Is Syncom Formulations (India) a debt-free company?

Syncom Formulations (India) is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Syncom Formulations (India)'s latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Syncom Formulations (India) reported revenue of ₹135 Cr, −9.0% year on year, and net profit of ₹25 Cr, +42.3% year on year.

### How has Syncom Formulations (India) stock performed over the last year?

Syncom Formulations (India)'s share price has risen 38.8% over the past year, +72.7% over three months and +15.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Syncom Formulations (India)?

As of 30 Jun 2026: promoters 50.57%, foreign institutions 0.35%, domestic institutions 0.00%, non-institutions 49.08%.

### Who are Syncom Formulations (India)'s competitors?

The listed Pharma & Healthcare companies closest to Syncom Formulations (India) by market cap are Dishman Carbogen Amcis, Vimta Labs, Medi Assist Healthcare Services, Indoco Remedies, Panacea Biotec and Sakar Healthcare.

### Is Syncom Formulations (India) a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Syncom Formulations (India)'s price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SYNCOMF against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.